Green Shield Canada (GSC), a not-for-profit health benefits company that offers employee group health benefits that supplement government-sponsored provincial health plans, has announced a new program to switch patients to biosimilar therapies.
Green Shield Canada (GSC), a not-for-profit health benefits company that offers employee group health benefits that supplement government-sponsored provincial health plans, has announced a new program to switch patients to biosimilar therapies.
Beginning in 2016, GSC began to prefer available biosimilars and follow-ons (which it then referred to as “subsequent-entry biologics”) on its formulary, and required patients initiating treatment to use these preferred products. GSC’s next effort is to implement a “biosimilar transition program” in which patients already receiving originator biologics will switch to biosimilars.
“The evidence has rapidly accumulated over the last [2] years, and it is all pointing in the same direction: patients can safely transition from an originator biologic to a biosimilar product with no loss of clinical benefit and no compromise in safety,” said the payer in a statement.
The program will initially apply to a select group of plans for patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis who are currently receiving branded etanercept (Enbrel) and infliximab (Remicade). As more biosimilars and more indications are approved, and as evidence on the feasibility of switching accumulates, the plan will increase the number of drugs and indications eligible for the transition program.
To help ensure a successful switch, the GSC says that it will use a “strong support system” that includes a dedicated team of care-coordinator nurses to help guide patients through the process, and news of the switch will be communicated to patients via a letter that outlines their options. First, patients may choose to undertake the switch after having discussed it with their provider. Second, they may choose to continue on their current treatment and pay the difference in costs between the biosimilar and the reference starting 60 days after the date of the letter. No claims for originator biologics will be denied; all claims will be paid based on the price of the biosimilar.
GSC has long been vocal in its calls for private payers in Canada to make greater use of biosimilars for the purpose of cost containment. In a statement in September 2017, the payer said that, though it has just 7% market share in Canada, due to its policy of beginning new starts on biosimilars, it generated 37% of claims for biosimilar infliximab (Inflectra) in the private market.
The payer has called on fellow companies to stop “signing up for the easy deals” in contracts with reference product sponsors to secure formulary placement. “We’re hoping to see more of our friends in the industry join us to support building a viable biosimilar market in Canada through forward-looking strategies. We did it for generics last decade, so we can do it again.”
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.